Search clinical trials for: ACH-0144471

Total 2308 results

Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, New Zealand, Korea, Republic of, Italy
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of a Single Dose of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Healthy | Renal Dysfunction

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Multiple Doses of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals

Completed

A Study of the Effects of Food and Age on Danicopan

Healthy

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Radiolabeled Danicopan in Healthy Male Participants

Healthy

New Zealand
Alexion Pharmaceuticals

Completed

Study of Danicopan in Participants of Japanese Descent

Healthy

Australia
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Thailand, Korea, Republic of, United Kingdom, Israel, Czechia, Greece, Poland, Brazil, Japan, Canada, Malaysia
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Healthy

United Kingdom
Alexion Pharmaceuticals
Celerion

Completed

Study of the Metabolism of Danicopan in Healthy Adults

Healthy

United States
Seoul National University Hospital
National Evidence-Based Healthcare Collaborating Agency; National Clinical... and other collaborators

Completed

Efficacy of Self-education Program for Advanced Care Planning(RCT) for General Population

Healthy

Korea, Republic of
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Healthy

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Single-dose ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Multiple Doses of ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion

Completed

Study of ALXN2050 in Participants With Renal Impairment

Healthy | Renal Impairment

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
Alexion Pharmaceuticals

Completed

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Healthy

United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis | Myasthenia Gravis

United States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
Syneos Health
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

Healthy Volunteers

Australia
Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
University of Zagreb
Croatian Institute of Health Insurance

Completed

Study of Autologous Conditioned Serum After Anterior Cruciate Ligament Reconstructive Surgery

Joint Instability

Croatia
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

Healthy

United States
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Alexion Pharmaceuticals
Parexel

Completed

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Healthy Adult Participants

United States
Hangzhou Endonom Medtech Co., Ltd.

Active, not recruiting

Guo's Aortic Arch Reconstruction: The First in Man Study of WeFlow-Arch Modular Embedded Branch Stent Graft System

Aortic Arch; Aneurysm, Dissecting

China
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Lupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LN

Australia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

HCV Infection

United States, Germany, Netherlands
Zhejiang Cancer Hospital

Completed

The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery

Ovarian Neoplasm Epithelial
Mayo Clinic

Enrolling by invitation

Effect of Advanced Care at Home vs. Traditional Brick-and-Mortar Hospital Care in Acutely Ill Adults: A Pragmatic Clinical Trial

Acute Illness

United States
Mayo Clinic

Terminated

Effect of Advanced Care at Home vs. Traditional Brick-and-Mortar Hospital Care in Acutely Ill Adults: A Randomized Clinical Trial

The Trial Will Compare Two Care Delivery Models That Are Currently Being Used in Routine Practice Settings for Acute Hospitalization

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Hepatitis C, Chronic

United States, Canada
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Second Affiliated Hospital, School of Medicine,...

Recruiting

Arthroscopic Anterior Cruciate Ligament Repair Versus Reconstruction for Acute Anterior Cruciate Ligament Injury

Anterior Cruciate Ligament Injuries

China
Universidad de Granada

Completed

Clinical Study on the Use of Symbios Xenograft for Sinus Floor Elevation

Sinus Floor Augmentation

Spain
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Ascopharm Groupe Novasco
Ramsay Générale de Santé

Unknown

ACL Versus ALL + ACL Study

Anterior Cruciate Ligament Injury | Ligament Rupture

France
Ace Cells Lab Limited

Unknown

Revitalization of Damaged Skin Due to Chronic Skin Diseases

Psoriasis | Atopic Dermatitis | Chronic Eczema

Serbia, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Azusa Pacific University

Withdrawn

Culturally Tailored ACT for Black Trauma

Anxiety Disorders | Stress Disorders, Traumatic | Anxiety

United States
Lars Konradsen

Unknown

The Best Method for ACL Reconstruction.

Anterior Cruciate Ligament Reconstruction

Denmark
JMackem Co., Ltd
Seoul National University Hospital

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

Diabetic Neuropathies | Neuropathic Pain | Post Herpetic Neuralgia

Korea, Republic of
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany

Search clinical trials for: ACH-0144471

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations